TY - JOUR
T1 - Could definitive radiotherapy be a treatment option for lymphoepithelial carcinoma of major salivary gland
T2 - Comparison of clinical outcomes of upfront surgery and upfront chemoradiotherapy
AU - Qiu, Zichen
AU - Wu, Zheng
AU - Zhou, Xiong
AU - Lin, Feifei
AU - Lyu, Shaowen
AU - Su, Yong
AU - Tao, Yalan
N1 - Funding Information:
Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee of Affiliated Hospital of Sun Yat-sen University Cancer Center, and the need for written informed consent was waived.
Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Objectives: The optimal treatment and associated clinical outcomes for lymphoepithelial carcinoma of the major salivary gland (LECSG) are currently unclear. As such, the purpose of this study was to assess the survival rates of LECSG patients who received either upfront surgery or upfront chemoradiotherapy (CRT). Materials and methods: In this retrospective study, we analyzed cases of LECSG patients treated at our center from January 2010 to April 2021. The cumulative incidences of overall survival rate (OS) and locoregional failure-free survival rate (LRFFS) were evaluated using the Kaplan-Meier method. In order to balance potential risk factors between the treatment groups, we conducted propensity score matching (PSM) at a 1:1 ratio. Results: The study enrolled a total of 107 patients, among whom 24 received surgery alone, 56 underwent surgery combined with postoperative radiotherapy, and 27 underwent definitive radiotherapy. The 5-year LRFFS rate and 5-year OS rate for the entire cohort were 86.6% and 84.4%, respectively. Following PSM, the 5-year LRFFS and OS rates for the upfront CRT cases were comparable to those of upfront surgery, both before and after matching. However, the upfront surgery group showed a tendency toward more de novo facial nerve injury and post-treatment facial nerve injury. Conclusion: The results of this study suggest that upfront CRT is as effective as upfront surgery in terms of locoregional control and overall survival for LECSG patients. Therefore, upfront CRT could be considered a viable treatment option, potentially avoiding the risks associated with surgical intervention.
AB - Objectives: The optimal treatment and associated clinical outcomes for lymphoepithelial carcinoma of the major salivary gland (LECSG) are currently unclear. As such, the purpose of this study was to assess the survival rates of LECSG patients who received either upfront surgery or upfront chemoradiotherapy (CRT). Materials and methods: In this retrospective study, we analyzed cases of LECSG patients treated at our center from January 2010 to April 2021. The cumulative incidences of overall survival rate (OS) and locoregional failure-free survival rate (LRFFS) were evaluated using the Kaplan-Meier method. In order to balance potential risk factors between the treatment groups, we conducted propensity score matching (PSM) at a 1:1 ratio. Results: The study enrolled a total of 107 patients, among whom 24 received surgery alone, 56 underwent surgery combined with postoperative radiotherapy, and 27 underwent definitive radiotherapy. The 5-year LRFFS rate and 5-year OS rate for the entire cohort were 86.6% and 84.4%, respectively. Following PSM, the 5-year LRFFS and OS rates for the upfront CRT cases were comparable to those of upfront surgery, both before and after matching. However, the upfront surgery group showed a tendency toward more de novo facial nerve injury and post-treatment facial nerve injury. Conclusion: The results of this study suggest that upfront CRT is as effective as upfront surgery in terms of locoregional control and overall survival for LECSG patients. Therefore, upfront CRT could be considered a viable treatment option, potentially avoiding the risks associated with surgical intervention.
KW - Definitive radiotherapy
KW - Intensity-modulated radiotherapy
KW - Lymphoepithelial carcinoma of the major salivary gland
U2 - 10.1016/j.oraloncology.2023.106443
DO - 10.1016/j.oraloncology.2023.106443
M3 - Article
C2 - 37295063
SN - 1368-8375
VL - 143
JO - Oral Oncology
JF - Oral Oncology
IS - 1
M1 - 106443
ER -